Paciraa (PCRX) October Exparel Data Suggests Q4 at Risk - BMO Capital

November 23, 2016 11:07 AM EST
Get Alerts PCRX Hot Sheet
Price: $30.65 +1.32%

Rating Summary:
    10 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 28 | Down: 20 | New: 17
Trade PCRX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

BMO Capital analyst Gary Nachman weighed in on Pacira Pharmaceuticals (NASDAQ: PCRX) after Symphony data were released today and October Exparel sales were $20.2mn, down 12% Y/Y and down 9% M/M. On a sales per selling day basis, Exparel declined 8% Y/Y and 5% M/M. PCRX recently reduced Exparel sales guidance to $263-268mn from $270-280mn along with 3Q results (we're at $263mn).

The October Exparel sales indicate meaningful growth is required for the remainder of 4Q to achieve the guidance. "We believe October is not a great start to 4Q and see a potential challenge in PCRX achieving even the low end of its guidance range," the analyst said.

The firm maintained a Market Perform rating and price target of $35.00

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $34.35 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA, Trader Talk

Related Entities

BMO Capital

Add Your Comment